Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-39.72M | $-22.61 |
| 2024 | $0.00 | $2.78M | $2.75 |
| 2023 | $0.00 | $-17.51M | $-35.50 |
| 2022 | $0.00 | $-18.06B | $-60.25 |
| 2021 | $16.7K | $-11.98M | $-51.77 |
Social Signal Score
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $-1.60 per share
Typical surprise -18.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-1.28 vs $-1.38beat
- Mon, May 11$-1.26 vs $-1.06miss
- Wed, Mar 25$-4.11 vs $-4.66beat
- Wed, Nov 12$-6.00 vs $-3.75miss
- Wed, Aug 13$-0.29 vs $-0.22miss
- Mon, May 12$-0.21 vs $-0.12miss
Estimates and results for PMN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
PMNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsmarketbeat.com·1d ago·Neutral
Promis Neurosciences Q2 Earnings Call Highlights Promis Neurosciences NASDAQ: PMN reported second-quarter 2026 results and highlighted blinded six-month interim data from its Phase 1b PRECISE-AD study of PMN310, an investigational antibody for early Alzheimer's disease.
View source ↗